


II. REMARKS

The Communication concerns Applicants' Response filed on March 12, 2007, wherein Applicants elected SEQ ID NO:124 as the species of the bioconjugate. The Communication states that the sequence elected is not a peptide and therefore does not read upon the invention previously elected in Applicants' response filed October 3, 2006, in reply to the Restriction Requirement mailed July 3, 2006.

Applicants have determined that the numbering of the sequences in the previously submitted Sequence Listing was incorrect as it relates to the numbering of the sequences in the specification. Applicants have therefore corrected the numbering of the sequences in the Sequence Listing and are submitting concurrently herewith a substitute Sequence Listing as text through EFS-Web. The substitute Sequence Listing correctly lists SEQ ID NO:124 as the peptide sequence which Applicants wish to elect as the species of the bioconjugate. No new matter is added by this amendment or the substitute Sequence Listing.

The Examiner is invited to contact the Applicants' undersigned attorney at (512) 536-3035 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
512.536.3035 (voice)
512.536.4598 (fax)

Date: August 10, 2007